

Oncology


Longer Term Investments (LTI)

As we age our cells mutate in new ways that can cause cancer. As life expectancy rises the number of new cancer patients will outpace population and GDP growth. Improvements in treatment should drive above-GDP sales growth for relevant companies.

Projections and opportunities

New cancer cases

Over 14 million new cancer cases occurred globally in 2012, a figure that could rise to over 20 million by 2030.



Source: WHO, American Cancer Society

The cost of cancer


The annual global financial cost of cancer has been estimated at USD 1.16 trillion in 2010, and this figure is expected to rise steadily.



Source: WHO

Cancer a global problem

Cancer is no longer just a problem in Western countries. Cancer is now the leading cause of death in China, and the country accounts for 22% of new cancer cases globally.



Source: WHO

Lachlan Towart, Analyst, UBS Switzerland AG

This report has been prepared by UBS Switzerland AG Please see important disclaimers and disclosures at the end of the document.

Cancer therapeutics market


The market for cancer therapeutics could exceed USD 150bn by 2020, up from around USD 100bn in 2015. Longer-term we expect the market to grow in mid- to high-single digits.



Source: UBS as of June 2018

Leading cause of death

Cancer remains a leading cause of death; 8.8m deaths globally in 2015. Five-year survival rates for all cancers diagnosed between 2007 and 2013 was 67%, up from 49% in 1975 to 1977.



Source: American Cancer Society

New cancer treatments


Beyond drug treatments, a number of cell therapies have now been approved for use. These offer the hope of long-lasting remission based on one-off treatments, albeit in a small number of patients so far.



Source: UBS



Oncology investment properties



○ Influencer ⊗ Key drivers



Near-term drivers

- Clinical trial results.
- Sales trajectory of novel cancer agents.
- Easing political pressure on drugs industry.



Sustainable investing impact

- Biopharmaceutical companies with strong exposure to oncology.



Impact investing (UN SDGs)

- SDG 3: Good health and well-being.

To learn more contact your financial advisor or go to: ubs.com/lti

